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Abstract
Exposure to 70% N2O evokes a robust antinociceptive effect in C57BL/6 (B6) but not in DBA/2 (D2)
inbred mice. This study was conducted to identify quantitative trait loci (QTL) in the mouse genome that
might determine responsiveness to N2O. Offspring from the F2 generation bred from B6 and D2
progenitors exhibited a broad range of responsiveness to N2O antinociception as determined by the
acetic acid-induced abdominal constriction test. QTL analysis was then used to dissect this continuous
trait distribution into component loci, and to map them to broad chromosomal regions. To this end,
24 spleens were collected from each of the following four groups: male and female F2mice responding
to 70% N2O in oxygen with 100% response (high-responders); and male and female F2 mice responding
with 0% response (low-responders). Genomic DNA was extracted from the spleens and genotyped with
simple sequence length polymorphism MapPairs markers. Findings were combined with findings from
the earlier QTL analysis from BXD recombinant inbred mice [Brain Res 725 (1996) 23]. Combined results
revealed two significant QTL that influence responsiveness to nitrous oxide on proximal chromosome
2 and distal chromosome 5, and one suggestive QTL on midchromosome 18. The chromosome 2 QTL
was evident only in males. A significant interaction was found between a locus on chromosome 6 and
another on chromosome 13 with a substantial effect on N2O antinociception.
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The simple inorganic pharmacological gas N2O produces a prominent antinociceptive effect in
experimental animals as well as clinical analgesia in human patients (Finck, 1985). Though long thought
to be due to a nonspecific depression of CNS function (Sonnenschein et al., 1948), this drug effect of N2O
is now known to involve the activation of endogenous opioid systems (Quock and Vaughn,
1995; Fujinaga and Maze, 2002). This was clearly shown by Berkowitz and his associates who found that
N2O antinociception in mice and rats was antagonized by the opioid receptor blocker naloxone
(Berkowitz et al., 1976, 1977) and that morphine-tolerant animals were cross-tolerant to N2O (Berkowitz
et al., 1977, Berkowitz et al., 1979). The first elaboration of these findings using subtype-selective opioid
receptor blockers was conducted by our laboratory and demonstrated that in the mouse abdominal
constriction test, N2O antinociception is specifically mediated by κ opioid receptors (Quock et al., 1990).
This was verified by a receptor protection experiment in which co-administration of a κ opioid ligand
protected N2O antinociception from antagonism by a non-selective opioid receptor alkylating
antagonist, β-chlornaltrexamine (Quock and Mueller, 1991). More recent studies utilizing rabbit antisera
against opioid peptides demonstrated that these κ opioid receptors were activated by dynorphin
fragments during N2O antinociception (Branda et al., 2000, Cahill et al., 2000).
In research utilizing inbred mouse strains, we discovered that, compared with the C57BL/6 (B6) strain,
DBA/2 (D2) mice were significantly less responsive to N2O antinociception (Quock et al., 1993). To
further investigate the mechanism of N2O antinociception, more recent studies have utilized a
pharmacogenetic approach to identify quantitative trait loci (QTL) in the mouse genome that might
determine responsiveness to N2O. A study conducted in BXD recombinant inbred mice derived from the
B6 and D2 strains identified some provisional QTL that determine responsiveness to N2O (Quock et al.,

1996). The present study was conducted in a large population of the F2 generation bred from the B6 and
D2 progenitors to confirm the identities of these QTL.

Experimental procedures
Animals

A breeding colony was established with male and female B6D2 F1 mice (Charles River Laboratories,
Charles River, MA, USA). Nearly 500 offspring from the F2 generation were bred and housed in an
AAALAC-accredited temperature- and humidity-regulated vivarium with a 12-h light/dark cycle. Food
and water were available ad libitum.
All experiments were approved by an institutional animal care and use committee and were conducted
in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals
(NIH publications no. 80-23, revised 1996). All efforts were made to minimize the number of animals
used and their suffering.

Antinociceptive testing

Antinociceptive responses were assessed using the abdominal constriction test. At 7–8 weeks of age,
mice were treated intraperitoneally with 0.1 ml per 10 g body weight of 0.6% acetic acid; exactly 5 min
later, the number of abdominal constrictions—lengthwise stretches of the torso with concave arching of
the back—in each animal was counted for a 6-min period in an atmosphere of air from a compressed air
cylinder. One week later, they were again tested for responsiveness to 0.6% acetic acid but this time in
an atmosphere of 70% N2O in oxygen (O2). The degree of antinociception (inhibition of abdominal
constrictions) produced by N2O in each animal was calculated as:
% antinociception = 100
# 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑖𝑖𝑖𝑖 𝑐𝑐𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 𝑎𝑎𝑎𝑎𝑎𝑎 − # 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑖𝑖𝑖𝑖 𝑁𝑁2 𝑂𝑂
# 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑖𝑖𝑖𝑖 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑎𝑎𝑎𝑎𝑎𝑎

Exposure to N2O

Groups of five mice each were placed inside a Plexiglas exposure chamber (20 cm W×35 cm L×15 cm H)
immediately following treatment with acetic acid. A mixture of 70% N2O, U.S.P. and 30% O2, U.S.P.
(Rockford Industrial Gas, Rockford, IL, USA) was delivered into the chamber via a length of polyethylene
tubing during a 5-min filling time using a portable N2O/O2 dental sedation system (Porter, Hatfield, PA,
USA). A POET II anesthetic monitoring system (Criticare, Milwaukee, WI, USA) was used to ascertain that
desired N2O/O2 atmospheres had been attained. Exhausted gas was vented to a fume hood via a second
length of polyethylene tubing. Control mice were exposed to compressed air, U.S.P. delivered into the
chamber at the same inflow rate (10 l/min).

QTL analysis

Following antinociceptive testing, mice were killed. The spleens were dissected from all mice, stored in
cryovials containing 0.5 ml physiological saline and saved at −20 °C. Genomic DNA was extracted from
the spleens by Nucleic Acid Purifications (Huntsville, Alabama). Genotyping was accomplished by
Research Genetics Inc. (Huntsville, AL, USA) with simple sequence length polymorphism MapPairs
markers (Jacob et al., 1995).

Selective genotyping was used where only the extreme high and low scoring tails of the trait distribution
were genotyped, a total of 96 of 493 mice. The proportion of genotyped mice of 19.5% (both tails
combined) contained 64% of the QTL information as do all 493 mice, but required only about one-fifth
of the genotyping cost (Lander and Botstein, 1989, Darvasi and Soller, 1992). A total of 77 markers were
genotyped, a process that determines which genotype each mouse possesses at each marker. The
average interval between markers was 19 cM with no interval greater than 33 cM. In an F2 mouse, the
genotype at any one marker is either homozygous B6, homozygous D2 or heterozygote. Several markers
were genotyped on each chromosome, and any marker whose genetic variation significantly covaried
with trait variation provided evidence for the presence of a QTL near the marker. The marker genotype
and trait data were analyzed for QTL and for interactions between loci (epistasis) using the
Pseudomarker 0.9 program package written for the MATLAB (Mathworks Inc., Natick, MA, USA)
programming environment (Sen and Churchill, 2001; obtained from www.jax.org/research/churchill)
using default settings except where noted otherwise. This program uses Monte Carlo computer
sampling to estimate the most likely values of unknown parameters (QTL genotypes, locations, missing
data) using Bayesian methods. Sixty-four imputations (samplings) of unknown genotypes based on the
observed marker data were made at 5 cM intervals, which approximates interval mapping at this
resolution. This was followed by 2.5 cM mapping for the more interesting chromosomes. This program
package analyzes the phenotypic effect of each marker or marker interval taken singly (MAINSCAN), but
also the phenotypic effects of pairs of markers or intervals taken jointly (PAIRSCAN) for their effects on
the trait. The latter allows a genome-wide search for epistasis, which are interactions between loci.
The criterion for statistical significance was based on a genome-wide P<0.05 estimated by permutation
tests on F2 data. This method takes the trait data for individual mice, and reassigns them at random to
the genotypes 1000 times. This simulates the null hypothesis that there are no QTL anywhere in the
genome, thus any apparent QTL are, by definition, false positives (Churchill and Doerge, 1994). The 5%
highest LOD scores were identified and the threshold, which separates them from the other 95%, was
taken as the genome-wide empirical significance threshold for this data set. This value was P=0.0002 for
single markers or intervals (MAINSCAN). The threshold for a suggestive QTL was P=0.005, which allows
an average of one false positive QTL genome-wide (Lander and Kruglyak, 1995). These P values
correspond to LOD 3.7 and 2.3, respectively, df=2, based on the expression LOD (logarithm of the
odds)=−log10(P). For the BXD data, we used P=0.0002 as our significant criterion determined by
permutation tests carried out in the same manner as the F2.
The P values from both BXD and F2 data for the same or similar markers were combined using Fisher's
method for combining P values from independent experiments testing the same hypothesis (Sokal and
Rohlf, 1995; Belknap et al., 1996). This was done only when the direction of QTL effect, or which allele
was associated with higher trait scores, was the same in both BXD and F2 data. For the combined results,
we used the average of the F2 and BXD thresholds, or P=0.0002 (LOD 3.7) for significant, and P=0.005
(LOD 2.3) for suggestive.
For tests of epistasis (PAIRSCAN), we required that the combined (or full model) effects on the trait of a
marker pair, which reflects the main effects of both markers plus their interaction, exceed the threshold
for significance (5% genome-wide error rate) estimated by a permutation test carried out using
the Pseudomarker PAIRSCAN program on F2 data. In this study, the threshold was set at LOD 7.9
(df=8, P=1.5×10−5) based on 500 permutations. When the combined effects of a marker pair were
significant, we then tested for their interaction at a significance threshold of P<0.01 (Sen and Churchill,

2001). This approach represents a conditional search for epistasis because only marker pairs attaining
significance for their joint effects on a trait (the condition) are tested for possible interactions. This
greatly reduces the number of pairs tested for interactions (only two in this study), and thus the rate of
false positive interactions compared with an unconditional search (Hood et al., 2001).
For those QTL attaining either suggestive or significant status (three QTL), we looked at the F2 data to
determine whether there were gender differences in QTL effect magnitude. Because we looked at only
three chromosomal regions, the threshold for significance for the gender difference was P=0.05/3, or
0.0167. This is equivalent to a LOD score difference of 1.8 between the two genders. Because the BXD
data (Quock et al., 1996) were collected on males only, only the F2 was useful for assessing gender
differences.

Results

A total of 493 F2 mice were tested for antinociceptive responsiveness to 70% N2O. The distribution of
their responsiveness to N2O is shown in Fig. 1. When genders were combined, roughly one quarter of
the F2 mice exhibited less than 10% antinociceptive response, which includes hyperalgesic response, and
roughly one quarter of the F2 mice exhibited 90–100% antinociceptive response. When only the 220
male F2 mice were considered, roughly 22% showed less than 10% antinociceptive response, while
roughly 32% showed 90–100% antinociceptive response. When only the 273 female F2 mice were
considered, roughly 31% showed less than 10% antinociceptive response, while 22% showed 90–100%
antinociceptive response. However, to insure equal representation for QTL analysis, the mice chosen for
genotyping (N=96) were evenly split between the high and low tails of the distribution and also between
the two genders.

Fig. 1. Distribution of antinociceptive responsiveness of F2 offspring to N2O. The classification of responsiveness to
N2O antinociception was based on the following ranges of antinociceptive response to 70% N2O: high, 90–100%;

intermediate, 11–89%; and low, <10% (including hyperalgesic responses or negative antinociceptive response). The
number of animals screened was 220 male F2 mice and 273 female F2 mice for a grand total of 493 F2 mice.

The MAINSCAN F2 results are shown in Fig. 2. Of the 20 mouse chromosomes in our genome scan, only
those 10 showing at least P<0.01 for a QTL or an interaction are shown. The most promising QTL were
on proximal chromosome 2, distal chromosome 5 and distal chromosome 18, all showing LOD>2.0 for
the F2 data alone. These were very near the markers D2Mit91, D5Mit409 and D18Mit186 at 42, 89 and
45 cM, respectively. For the chromosomes 2 and 5 QTL, the B6 allele conferred higher antinociception
scores than did the D2 allele, while the opposite was the case for the chromosome 18 QTL. This same
pattern of results was also observed in our BXD study (Quock et al., 1996).

Fig. 2. LOD score plot (df=2) of F2 QTL data at 2.5 cM resolution using the program MAINSCAN (Sen and Churchill,
2001). From the LOD scores presented, P values can be obtained from the expression P=10−LOD. Only those
chromosomes showing at least P<0.01 for a main effect in MAINSCAN or for an interaction in PAIRSCAN are shown.

The PAIRSCAN results are shown in Fig. 2 for the same 10 chromosomes shown in Fig. 2. This analysis
found one significant interaction (P=3×10−5), that between a locus on chromosome 13 and another on
chromosome 6, as shown by the arrow in Fig. 3. Fig. 4 shows this same interaction in terms of the
antinociception scores for all nine genotypes possible between these two interacting loci. An interaction
primarily of the dominance×dominance type is demonstrated by the fact that the heterozygotes at
chromosome 13 show very high antinociception when the chromosome 6 genotype is homozygous B6
(shown as BB), but in marked contrast, the chromosome 13 heterozygotes show very low
antinociception when the chromosome 6 genotype is either heterozygous or homozygous D2 (shown as
Het or DD). Neither locus had a significant main effect in the MAINSCAN analysis, but emerged as
significant only in the PAIRSCAN analysis due mainly to the strength of the interaction (P=3×10−5). The
numbers of mice per group are shown within each bar of Fig. 4.

Fig. 3. Two-dimensional plot of PAIRSCAN results for the 10 chromosomes of greatest interest shown in Fig. 1. The
lower half shows the LOD scores for the full model (df=8) for marker pairs, which includes the main effects of each
marker plus their interaction, while the upper half shows LOD scores for the interaction alone (df=4). Areas in
white failed to attain P<0.05 (<LOD 3.4 lower plot, <LOD 2.1 upper plot), while those exceeding this relaxed
criterion are shaded from gray to black as a function of the LOD score scale shown at right. For visual clarity, the
LOD scores in the upper half were increased by 1.64-fold. The one significant interaction (P=3×10−5) is denoted by
the arrow. Several other interactions are shown, but our sample size did not have sufficient power to detect them
as suggestive or significant (see Experimental Procedures).

Fig. 4. The degree of N2O antinociception (divided by 100) by genotype for the D13Mit4 marker on chromosome
13 as a function of genotype at another locus (D6Mit116) on chromosome 6. The genotypes are symbolized BB,
Het and DD, which stand for B6 homozygotes, heterozygotes and D2 homozygotes, respectively. An interaction
(P=3×10−5) predominantly of the dominance×dominant type is demonstrated by the fact that the heterozygotes at
chromosome 13 show very high antinociception when the chromosome 6 genotype is homozygous BB, but show
very low antinociception when the chromosome 6 genotype is either heterozygous or homozygous DD. The
numbers of mice per group are shown within each bar.

These MAINSCAN F2 findings were combined with the earlier QTL analysis from BXD recombinant inbred
mice (Quock et al., 1996). The combined results are shown in Table 1. The overall results when
the Pvalues from both populations were combined revealed two significant and one suggestive QTL. The
significant QTL were on proximal chromosome 2 (P=5×10−5) and distal chromosome 5 (P=1.3×10−4),
while the suggestive QTL was on distal chromosome 18 (P=5×10−4). These three were very near the
markers D2Mit91, D5Mit409 and D18Mit186 at 42, 89 and 45 cM, respectively. However, the 95%
confidence intervals for map location are in the range of about 20–35 cM for the two significant QTL
(Darvasi and Soller, 1997), or about one-quarter to one-third the length of each chromosome. Table

1 also shows the proportion of the phenotypic (trait) variance expressed as a percent (%var) due to each
of these three QTL that has been corrected for the upward bias that selective genotyping causes. The
upward bias was estimated to be three-fold (Darvasi and Soller, 1992), thus the correction factor was
0.33. Because of this, the %var values given in Table 1 are estimates of what we would have observed
had we genotyped all 493 mice in our study instead of only the top and bottom 10%.
Table 1. QTL that determine responsiveness to 70% N2O for BXD and F2data separately and for their
combined P using Fisher's method for combining P values from independent experiments testing the
same hypothesisa
BXD marker, F2marker
D2Mit58, D2Mit91
lapls2–5, D5Mit409
lapls3–12, D18Mit186

Chromosome
2
5
18

BXD cM
51
93
43

BXD P
0.007
0.005
0.007

F2cM
44
85
45

F2 P
0.0005
0.002
0.006

Combined P
5.0 × 10−5
1.3 × 10−4
4.7 × 10−4

F2 %var, dom
5.1%, partial D2 dom
3.7%, partial B6 dom
3.1%, B6 overdom

Only those QTL attaining either suggestive (chromosome 18) or significant status are shown based on
the combined results (2nd column from right). For the F2, data are for both genders combined.
a

When these three QTL were examined for gender differences, the chromosome 2 QTL showed a
significant gender difference, with LOD 2.43 in males and LOD 0.39 in females (P=0.008 for the gender
difference). This value for the chromosome 5 QTL was P=0.04 and for the chromosome 18 was P=0.06,
both not significant. For all three, the QTL effect sizes (%var) were over two-fold larger in males than
females, although this was significant only for chromosome 2.
Because our BXD study used only males, it is instructive to combine these results with only the male
results from the F2. The results were closely similar to those given when the F2 data were based on both
genders together (shown in Table 1) because all three QTL had larger effect sizes in males than females.
The combined P for chromosomes 2, 5 and 18 were 2×10−4, 7×10−5 and 5×10−4, respectively, which
compared well to the combined Ps when both genders were combined shown in Table 1.

Discussion
Previous research assessing the responsiveness to N2O antinociception in BXD recombinant inbred
mouse strains resulted in the identification of eight markers distributed over seven chromosomes that
were possibly associated with N2O antinociception at P<0.01 (Quock et al., 1996). Based on a
strong P value, accurate mapping of the marker, and a location in the middle of a sequence of markers
with high correlation, the strongest correlations observed were the following: Il2ra on chromosome 2
(P<0.002); Hbb on chromosome 7 (P<0.002); Hmg1rs7 on chromosome 16 (P<0.002); and Gs15 on
chromosome 19 (P<0.002). These QTL were suggestive rather than definitive because they fell well short
of the P<0.0001 level needed for statistical significance for BXD QTL data (Belknap et al., 1996).
When the present F2 QTL results were combined with the earlier QTL analysis from BXD recombinant
inbred mice (Quock et al., 1996), the results revealed two significant and one suggestive QTL that
influence responsiveness to N2O antinociception on mid chromosome 2, distal chromosome 5 and mid
chromosome 18. For the chromosomes 2 and 5 QTL, the B6 allele conferred higher antinociception
scores than did the D2 allele in both BXD and F2 populations, while the opposite was the case for
chromosome 18 QTL.
This study is among the few to carry out a full genome search for epistasis, or the interaction between
pairs of QTL in their influence on a trait of interest. To the usual additive and dominance variation as the

basis for detecting QTL in an F2 (MAINSCAN), we add epistasis as a third source of genetic variation to
facilitate detection (PAIRSCAN). The importance of an interaction lies in showing that both interacting
loci have to be examined for their joint effects on the trait rather than each locus examined singly, and
that interacting loci often are part of the same pathway or intertwined pathways, thus they can serve as
clues to function at the pathway level. Unfortunately, the power to detect interactions between pairs of
QTL is typically much smaller than that to detect single QTL in a given experiment. Nonetheless, a
significant interaction did emerge in the PAIRSCAN study, that between a locus on chromosome 6 and
another on chromosome 13. Thus, these two interacting QTL have now been detected as influencing
antinociception even though neither had even a suggestive effect when examined singly (MAINSCAN).
Most QTL studies make use of a single large mapping population, most often an F2 intercross between
two inbred strains. This approach has a proven track record, and there is much to recommend it.
However, in the present study we used two mapping populations for a number of reasons. The first is
that replication of QTL results can be tested, and those that pass the test are more likely to represent
robust QTL effects relatively insensitive to the influence of varying genetic background (inbred vs.
segregating) and fluctuations in laboratory environment over time. Second, the specific strengths of
each mapping population can be exploited to gain additional genetic information. For example, RI sets
are very efficient in the detection of genetic correlations between two or more traits, while the F2 is the
least efficient for this purpose (Crabbe et al., 1990). Third, one of the populations (RI) is inbred strains
providing stable and replicable genotypes. This allows the accumulation of genetic data across time and
laboratories on the same genotypes or strains.
The QTL analysis used here is an example of a trait-driven analysis aimed ultimately at the discovery of
new genes that are known from the outset to be trait relevant. Knowing the approximate map location
of a QTL is often the all-important first step toward identifying the specific gene underlying a QTL. This is
because of the large and increasing number of mapped genes of obvious neurochemical import in the
mouse, making it likely that QTL map sites emerging from genome searches will immediately suggest
plausible candidate genes previously mapped to the same region.
At this early stage in genetic dissection, the map resolution of each of our significant QTL is rather broad
(20–35 cM), and consequently there are many genes within these intervals that may underlie our QTL.
However, one candidate gene is worth noting—Nos1 on chromosome 5 (65 cM), which encodes the
neuronal form of the enzyme nitric oxide synthase (NOS) (wwww.informatics.jax.org) and maps near to
our chromosome 5 QTL. This QTL has a peak LOD at 84 cM, but the confidence interval clearly
encompasses the Nos1 locus. The identification of this candidate gene is significant because in earlier
studies, we implicated nitric oxide in N2O antinociception. Pharmacological inhibition of NOS,
particularly the neuronal isoform, antagonized the antinociceptive effect of N2O in mice (McDonald et
al., 1994, Ishikawa and Quock, 2003b). A recent study also reported that exposure to N2O stimulated
NOS enzyme activity in brains of N2O-sensitive B6 mice but not N2O-insensitive D2 mice (Ishikawa and
Quock, 2003a). Though circumstantial, these results suggest that an insensitivity of the neuronal NOS
enzyme in D2 mice to stimulation by N2O may explain the insensitivity of the D2 strain to N2O
antinociception.
Further studies that can attain higher resolution mapping to 1 cM would narrow the number of possible
genes down to less than 20—of which about half would likely be expressed in brain—and provide
further evidence of the involvement of Nos1 and other genes in N2O antinociception.
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